Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy PhaseBio Pharmaceuticals stock

Learn how to easily invest in PhaseBio Pharmaceuticals stock.

PhaseBio Pharmaceuticals Inc is a biotechnology business based in the US. PhaseBio Pharmaceuticals shares (PHAS) are listed on the NASDAQ and all prices are listed in US Dollars. PhaseBio Pharmaceuticals employs 60 staff and has a trailing 12-month revenue of around $818,000.

How to buy shares in PhaseBio Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PHAS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

PhaseBio Pharmaceuticals stock price (NASDAQ: PHAS)

Use our graph to track the performance of PHAS stocks over time.

PhaseBio Pharmaceuticals shares at a glance

Information last updated 2022-09-25.
Latest market close$0.80
52-week range$0.50 - $4.10
50-day moving average $1.10
200-day moving average $1.32
Wall St. target price$13.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.38

Buy PhaseBio Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$100
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy PhaseBio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

PhaseBio Pharmaceuticals price performance over time

Historical closes compared with the close of $0.8 from 2022-09-23

1 week (2022-09-16) -20.00%
1 month (2022-08-25) -35.48%
3 months (2022-06-24) 17.66%
6 months (2022-03-24) -33.33%
1 year (2021-09-24) -73.60%
2 years (2020-09-25) -76.61%
3 years (2019-09-25) 4.84
5 years (2017-09-21) N/A

PhaseBio Pharmaceuticals financials

Revenue TTM $818,000
Gross profit TTM $-91,276,000
Return on assets TTM -106.07%
Return on equity TTM -3091.02%
Profit margin 0%
Book value $0.18
Market capitalisation $39.7 million

TTM: trailing 12 months

PhaseBio Pharmaceuticals share dividends

We're not expecting PhaseBio Pharmaceuticals to pay a dividend over the next 12 months.

PhaseBio Pharmaceuticals share price volatility

Over the last 12 months, PhaseBio Pharmaceuticals's shares have ranged in value from as little as $0.5 up to $4.1. A popular way to gauge a stock's volatility is its "beta".

PHAS.US volatility(beta: 2.45)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PhaseBio Pharmaceuticals's is 2.4498. This would suggest that PhaseBio Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

PhaseBio Pharmaceuticals overview

PhaseBio Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc.

Frequently asked questions

What percentage of PhaseBio Pharmaceuticals is owned by insiders or institutions?
Currently 6.746% of PhaseBio Pharmaceuticals shares are held by insiders and 55.508% by institutions.
How many people work for PhaseBio Pharmaceuticals?
Latest data suggests 60 work at PhaseBio Pharmaceuticals.
When does the fiscal year end for PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals's fiscal year ends in December.
Where is PhaseBio Pharmaceuticals based?
PhaseBio Pharmaceuticals's address is: 1 Great Valley Parkway, Malvern, PA, United States, 19355
What is PhaseBio Pharmaceuticals's ISIN number?
PhaseBio Pharmaceuticals's international securities identification number is: US7172241090
What is PhaseBio Pharmaceuticals's CUSIP number?
PhaseBio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 717224109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site